Connect with us

Hi, what are you looking for?

Economy

Recovered COVID patients likely protected for at least six months, study finds

LONDON — Almost all people previously infected with coronavirus disease 2019 (COVID-19) have high levels of antibodies for at least six months that are likely to protect them from reinfection with the disease, results of a major UK study showed on Wednesday.

Scientists said the study, which measured levels of previous COVID-19 infection in populations across Britain, as well as how long antibodies persisted in those infected, should provide some reassurance that swift cases of reinfection will be rare.

“The vast majority of people retain detectable antibodies for at least six months after infection with the coronavirus,” said Naomi Allen, a professor and chief scientist at the UK Biobank, where the study was carried out.

Among participants who had tested positive for previous COVID-19 infection, 99% retained antibodies to SARS-CoV-2 for three months, the results showed. After the full six months of follow-up in the study, 88% still had them.

“Although we cannot be certain how this relates to immunity, the results suggest that people may be protected against subsequent infection for at least six months following natural infection,” Allen said.

She said the findings were also consistent with results of other studies in the United Kingdom and Iceland which found that antibodies to the coronavirus tended to persist for several months in those who have had the disease and recovered.

A study of UK healthcare workers published last month found that people who have had COVID-19 were likely to be protected for at least five months, but noted that those with antibodies may still be able to carry and spread the virus.

The UK Biobank study also found that the proportion of the UK population with COVID-19 antibodies – a measure known as seroprevalence – rose from 6.6% at the start of the study period in May/June 2020 to 8.8% by November/December 2020.

SARS-CoV-2 seroprevalence was most common in London, at 12.4%, and least common in Scotland at 5.5%, it found. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

WASHINGTON D.C. — The United States is seeking to form a coalition of countries to drive negotiations on a global plastic pollution treaty, weeks...

Economy

By Diego Gabriel C. Robles  THE WORLD BANK (WB) upgraded its growth forecast for the Philippines for this year and 2023, citing an “accommodative”...

Economy

THE PHILIPPINE auto industry’s sales recovery will likely be derailed if a measure reimposing excise taxes on pickup trucks is signed into law, according...

Economy

THE BANGKO SENTRAL ng Pilipinas (BSP) may deliver a second off-cycle rate hike in early November when the US Federal Reserve is expected to...

Economy

THE ASIAN Development Bank (ADB) is planning to allocate at least $14 billion for a program aimed at easing a food crisis in the...

Investing

With the reversal of the 1.25% rise in National Insurance Contributions happening on the 6th of November, employers across the nation have an opportunity...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Investing

The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.